Aktis Oncology (AKTS) – What Are Brokerages Saying About This Stock?

Aktis Oncology (NASDAQ:AKTS) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $35.62.

Several research firms recently commented on AKTS. Wedbush reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Aktis Oncology in a report on Friday, October 2nd. Weiss Ratings cut Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. BMO Capital Markets assumed coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price objective on the stock. Oppenheimer assumed coverage on shares of Aktis Oncology in a report on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AKTS. GK Wealth Management LLC acquired a new stake in Aktis Oncology in the 3rd quarter worth approximately $26,000. State of Wyoming acquired a new position in Aktis Oncology during the second quarter worth $32,000. AXQ Capital LP bought a new stake in Aktis Oncology during the second quarter worth about $226,000. Susquehanna International Group LLP bought a new position in shares of Aktis Oncology in the second quarter valued at about $278,000. Finally, Deutsche Bank AG lifted its stake in shares of Aktis Oncology by 49.3% during the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock valued at $678,000 after acquiring an additional 6,942 shares during the period. 28.84% of the stock is owned by hedge funds and other institutional investors.

Aktis Oncology Price Performance

Shares of NASDAQ AKTS opened at $15.73 on Tuesday. Aktis Oncology has a 1-year low of $14.72 and a 1-year high of $34.19. The business’s 50 day moving average is $21.41 and its two-hundred day moving average is $21.16.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to analyst estimates of $2.70 million. On average, research analysts predict that Aktis Oncology will post -1.84 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is directed primarily toward therapies for solid tumors, an area where it seeks to improve the ability of the immune system to recognize and eliminate cancer cells.

Aktis Oncology is developing a pipeline of targeted oncology candidates based on proprietary immune-cell engagement technologies. These therapies are intended to direct immune cells toward tumor-associated targets and potentially address cancers that are difficult to treat with existing immunotherapies.

The company’s programs remain in development, and publicly available information about its commercial products, geographic operations, and leadership is limited.